Info@ThinkPinkRocks.com

Metastatic RCC patients may benefit from sequential TKI strategy

For patients with metastatic renal cell carcinoma, sequential tyrosine kinase inhibitor therapy may be better option than changing to a mammalian target of rapamycin inhibitor, research suggests.

View article:
Metastatic RCC patients may benefit from sequential TKI strategy

Share

Leave a Reply